Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Housing & Urban Development Corp., Paras Defence and Space Technologies Ltd. and Waaree Energies Ltd. are some stocks that ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...

Jio Financial Services and BlackRock further subscribed to Rs 5.85 crore shares of JV Jio BlackRock Asset Management for Rs ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

These three NDAs of Sitagliptin (base) and combination franchise had been approved by the USFDA earlier. (Image Credits: Pixabay) Zydus Lifesciences Ltd on Tuesday announced that it has entered ...

Currently, Nomura is factoring in a 5% decline in US revenues for Zydus Life in financial year 2026, in comparison to financial year 2025.